To date, the FDA has not approved a biosimilar product. In its own discussion of the merits and obstacles to biosimilar drugs, the ACR sponsored a panel session titled, “Biosimilar Products in the U.S. Market: Fact or Fiction?” at the 2011 ACR/ARHP Annual Scientific Meeting here in November.
Where Will Kinase Inhibitors Fit into the RA Treatment Mix?
Presenters at “Looking Ahead to Kinase Inhibition in Rheumatoid Arthritis,” a session here at the 2011 ACR/ARHP Annual Scientific Meeting, delved into some of the big questions that rheumatology faces with kinase inhibitor use.
Susac’s Syndrome: Confusion, Expressive Aphasia, Gait Instability
A 49-year-old man presented to the hospital with confusion, dysarthria, expressive aphasia, and progressive gait instability.
Information on New Drug Approvals and Medication Safety
Rheumatology-related drug safety, approvals, and what’s in the pipeline.
Challenges and Rewards of a Physician Executive Career
The job of a physician executive offers a different set of challenges for rheumatologists familiar with research and patient care.
A Comparison of the Canadian and U.S. Healthcare Systems
The joys and the hazards of the Canadian single-payer universal healthcare program Canadian and the high-capacity and costly U.S. healthcare system.
A Patient’s Perspective on RA
I was diagnosed in April 2010, at 44 years old, with seropositive RA; the disease rapidly turned my life upside down.
Coding Corner Answer: February’s Coding Challenge
A 62-year-old male patient returns to the office for a followup visit for his gout.
Arthritis Self-Management Program Success
Although effective, arthritis self-management programs can be challenging to implement.
Shortcomings and Promises of Genome-wide Association Studies
The outcomes of genome-wide association studies (GWAS) have not been what scientists expected, but researchers are developing new approaches to use revelatory GWAS information to identify genetic causal variants, predictors of treatment response, and future opportunities for genetic insight.